Positive News SentimentPositive News Tarsus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TARS) $16.53 +0.06 (+0.36%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$16.03▼$16.7750-Day Range$12.98▼$18.8652-Week Range$11.33▼$25.25Volume471,868 shsAverage Volume309,315 shsMarket Capitalization$547.14 millionP/E RatioN/ADividend YieldN/APrice Target$43.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Tarsus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside161.3% Upside$43.20 Price TargetShort InterestBearish13.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$272,472 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.86) to ($4.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector645th out of 948 stocksBiological Products, Except Diagnostic Industry108th out of 164 stocks 3.4 Analyst's Opinion Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.20, Tarsus Pharmaceuticals has a forecasted upside of 161.3% from its current price of $16.53.Amount of Analyst CoverageTarsus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.47% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 6.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARS. Previous Next 3.3 News and Social Media Coverage News SentimentTarsus Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tarsus Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for TARS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $272,472.00 in company stock.Percentage Held by Insiders11.54% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.02% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to decrease in the coming year, from ($4.86) to ($4.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Read More TARS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARS Stock News HeadlinesNovember 21, 2023 | msn.comGoldman Sachs Initiates Coverage of Tarsus Pharmaceuticals (TARS) with Neutral RecommendationNovember 21, 2023 | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Coverage Initiated by Analysts at The Goldman Sachs GroupDecember 1, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 20, 2023 | markets.businessinsider.comHold Rating on Tarsus Pharmaceuticals: Analysis of Xdemvy’s Market Challenges and Future PotentialNovember 20, 2023 | msn.comGoldman starts Tarsus at neutral, says Xdemvy launch faces headwindsNovember 17, 2023 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Tarsus Pharmaceuticals (TARS)November 12, 2023 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | finance.yahoo.comAnalysts Are Betting On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) With A Big Upgrade This WeekDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 11, 2023 | benzinga.comTarsus Pharmaceuticals Stock (NASDAQ:TARS), Analyst Ratings, Price Targets, PredictionsNovember 11, 2023 | markets.businessinsider.comPromising Market Performance and Strong Sales Projection Uphold Buy Rating for Tarsus PharmaceuticalsNovember 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Rani Therapeutics Holdings (RANI) and Novavax (NVAX)November 9, 2023 | msn.comTarsus files to sell $300M mixed securities shelfNovember 9, 2023 | msn.comTarsus Pharmaceuticals GAAP EPS of -$1.28 beats by $0.11, revenue of $1.9M beats by $1.54MNovember 9, 2023 | finance.yahoo.comTarsus Reports Third Quarter 2023 Financial Results and Recent Business AchievementsNovember 8, 2023 | morningstar.comTarsus Pharmaceuticals Inc Ordinary Shares TARSNovember 8, 2023 | finance.yahoo.comRecent uptick might appease Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) institutional owners after losing 11% over the past yearNovember 7, 2023 | finance.yahoo.comIntegriChain Presents The Tina Patel Shining Light Award to Patrick Townsend of Vertex PharmaceuticalsNovember 1, 2023 | finance.yahoo.comTarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023October 19, 2023 | msn.comTarsus Pharmaceuticals, Inc. - Barking Up The Wrong TreeSeptember 21, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Seelos Therapeutics (SEEL), Clene (CLNN)September 12, 2023 | nasdaq.comGuggenheim Maintains Tarsus Pharmaceuticals (TARS) Buy RecommendationSeptember 6, 2023 | finance.yahoo.comTarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex BlepharitisSeptember 4, 2023 | msn.comTarsus Pharmaceuticals: Worthy Of A Small BetAugust 30, 2023 | fool.comTarsus Pharmaceuticals (NASDAQ: TARS)August 24, 2023 | finance.yahoo.comNow Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex BlepharitisAugust 19, 2023 | finance.yahoo.comInsider Spends US$160k Buying More Shares In Tarsus PharmaceuticalsSee More Headlines Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TARS CUSIPN/A CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$43.20 High Stock Price Target$54.00 Low Stock Price Target$19.00 Potential Upside/Downside+163.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,090,000.00 Net MarginsN/A Pretax Margin-748.73% Return on Equity-59.14% Return on Assets-48.01% Debt Debt-to-Equity Ratio0.14 Current Ratio11.15 Quick Ratio11.15 Sales & Book Value Annual Sales$25.82 million Price / Sales21.01 Cash FlowN/A Price / Cash FlowN/A Book Value$6.45 per share Price / Book2.54Miscellaneous Outstanding Shares33,100,000Free Float29,285,000Market Cap$542.51 million OptionableNot Optionable Beta0.79 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, President, CEO & ChairmanDr. Bryan Wahl J.D. (Age 45)M.D., General Counsel & Corporate Secretary Comp: $619.09kDr. Elizabeth Yeu Lin M.D. (Age 45)Chief Medical Advisor & Director Comp: $286kDr. Jose Trevejo M.D. (Age 51)Ph.D., Chief Medical Officer Comp: $769.39kMr. Jeffrey S. Farrow (Age 61)CFO & Chief Strategy Officer Dr. Seshadri Neervannan Ph.D. (Age 55)Chief Operating Officer Comp: $486.67kMr. David NakasoneHead of Investor RelationsMs. Adrienne KempSenior Director of Corporate CommunicationsMr. Matthew Rossen M.B.A. (Age 46)Vice President of Marketing Mr. Scott YoumansVice President of SalesMore ExecutivesKey CompetitorsAnavex Life SciencesNASDAQ:AVXL4D Molecular TherapeuticsNASDAQ:FDMTIcosavaxNASDAQ:ICVXCaribou BiosciencesNASDAQ:CRBUCabaletta BioNASDAQ:CABAView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 793 shares on 11/30/2023Ownership: 0.032%Deutsche Bank AGBought 1,985 shares on 11/24/2023Ownership: 0.034%Tudor Investment Corp Et AlBought 50,000 shares on 11/16/2023Ownership: 0.151%Alps Advisors Inc.Bought 4,404 shares on 11/15/2023Ownership: 0.073%Legal & General Group PlcBought 7,471 shares on 11/15/2023Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions TARS Stock Analysis - Frequently Asked Questions Should I buy or sell Tarsus Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TARS shares. View TARS analyst ratings or view top-rated stocks. What is Tarsus Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 1 year target prices for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $19.00 to $54.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 161.3% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts. How have TARS shares performed in 2023? Tarsus Pharmaceuticals' stock was trading at $14.66 at the beginning of the year. Since then, TARS shares have increased by 12.8% and is now trading at $16.53. View the best growth stocks for 2023 here. When is Tarsus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our TARS earnings forecast. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $1 million. What ETF holds Tarsus Pharmaceuticals' stock ? Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio. When did Tarsus Pharmaceuticals IPO? (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.70%), Cowen AND Company LLC (5.51%), Deerfield Management Company L.P. Series C (2.28%), Artisan Partners Limited Partnership (1.22%), Allspring Global Investments Holdings LLC (0.75%) and Schonfeld Strategic Advisors LLC (0.74%). Insiders that own company stock include Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TARS) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.